Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1990 Aug;64(8):3779–3791. doi: 10.1128/jvi.64.8.3779-3791.1990

Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.

P L Nara 1, L Smit 1, N Dunlop 1, W Hatch 1, M Merges 1, D Waters 1, J Kelliher 1, R C Gallo 1, P J Fischinger 1, J Goudsmit 1
PMCID: PMC249673  PMID: 2370681

Abstract

Emergence in two chimpanzees of human immunodeficiency virus type 1 (HIV-1) IIIB variants resistant to neutralization by the preexisting antibody is described. Viruses isolated from the HIV-1 IIIB gp120-vaccinated and -challenged animal were more resistant to neutralization by the chimpanzee's own serum than viruses isolated from the naive infected animal, indicating immune pressure as the selective mechanism. However, all reisolated viruses were 16- to 256-fold more neutralization resistant than the inoculum virus to antibodies binding to the third variable domain (V3) of the HIV-1 external envelope. Early chimpanzee serum samples that neutralized the inoculum strain but not the reisolated viruses were found to bind an HIV-1 IIIB common nonapeptide (IQRGPGRAF) derived from the gp120 isolate-specific V3 domain shown to induce isolate-specific neutralization in other animals. Amplification of the V3 coding sequence by polymerase chain reaction and subsequent sequence analysis of the neutralization-resistant variants obtained from in vivo-infected animals indicated that early resistance to neutralization by an HIV-1 IIIB monoclonal antibody (0.5 beta) was conferred by changes outside the direct binding site for the selective neutralizing antibody. The reisolated neutralization-resistant isolates consisted of the lower-replication-competent virus subpopulations of the HIV-1 IIIB stock, as confirmed by biological and sequence analyses. In vitro passage of the HIV-1 IIIB stock through chimpanzee and human peripheral blood mononuclear cell cultures void of HIV-specific antibody resulted in homogenic amplification of the more-replication-competent subpopulation preexisting in the original viral stock, suggesting a role for the immune system in suppressing the more-replication-competent viruses.

Full text

PDF
3779

Images in this article

3782Image
on p.3782

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nyström G., Fenyö E. M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. 1990 Feb;4(2):107–112. doi: 10.1097/00002030-199002000-00002. [DOI] [PubMed] [Google Scholar]
  2. Albert J., Gaines H., Sönnerborg A., Nyström G., Pehrson P. O., Chiodi F., von Sydow M., Moberg L., Lidman K., Christensson B. Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. J Med Virol. 1987 Sep;23(1):67–73. doi: 10.1002/jmv.1890230108. [DOI] [PubMed] [Google Scholar]
  3. Alter H. J., Eichberg J. W., Masur H., Saxinger W. C., Gallo R., Macher A. M., Lane H. C., Fauci A. S. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science. 1984 Nov 2;226(4674):549–552. doi: 10.1126/science.6093251. [DOI] [PubMed] [Google Scholar]
  4. Arthur L. O., Bess J. W., Jr, Waters D. J., Pyle S. W., Kelliher J. C., Nara P. L., Krohn K., Robey W. G., Langlois A. J., Gallo R. C. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol. 1989 Dec;63(12):5046–5053. doi: 10.1128/jvi.63.12.5046-5053.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Arthur L. O., Pyle S. W., Nara P. L., Bess J. W., Jr, Gonda M. A., Kelliher J. C., Gilden R. V., Robey W. G., Bolognesi D. P., Gallo R. C. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8583–8587. doi: 10.1073/pnas.84.23.8583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Asjö B., Morfeldt-Månson L., Albert J., Biberfeld G., Karlsson A., Lidman K., Fenyö E. M. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. 1986 Sep 20;2(8508):660–662. [PubMed] [Google Scholar]
  7. Chanh T. C., Dreesman G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986 Nov;5(11):3065–3071. doi: 10.1002/j.1460-2075.1986.tb04607.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cheng-Mayer C., Seto D., Tateno M., Levy J. A. Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988 Apr 1;240(4848):80–82. doi: 10.1126/science.2832945. [DOI] [PubMed] [Google Scholar]
  9. Clements J. E., Gdovin S. L., Montelaro R. C., Narayan O. Antigenic variation in lentiviral diseases. Annu Rev Immunol. 1988;6:139–159. doi: 10.1146/annurev.iy.06.040188.001035. [DOI] [PubMed] [Google Scholar]
  10. Dalgleish A. G., Chanh T. C., Kennedy R. C., Kanda P., Clapham P. R., Weiss R. A. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology. 1988 Jul;165(1):209–215. doi: 10.1016/0042-6822(88)90674-5. [DOI] [PubMed] [Google Scholar]
  11. Eichberg J. W., Zarling J. M., Alter H. J., Levy J. A., Berman P. W., Gregory T., Lasky L. A., McClure J., Cobb K. E., Moran P. A. T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. J Virol. 1987 Dec;61(12):3804–3808. doi: 10.1128/jvi.61.12.3804-3808.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Francis D. P., Feorino P. M., Broderson J. R., McClure H. M., Getchell J. P., McGrath C. R., Swenson B., McDougal J. S., Palmer E. L., Harrison A. K. Infection of chimpanzees with lymphadenopathy-associated virus. Lancet. 1984 Dec 1;2(8414):1276–1277. doi: 10.1016/s0140-6736(84)92824-1. [DOI] [PubMed] [Google Scholar]
  13. Fultz P. N., McClure H. M., Swenson R. B., McGrath C. R., Brodie A., Getchell J. P., Jensen F. C., Anderson D. C., Broderson J. R., Francis D. P. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome. J Virol. 1986 Apr;58(1):116–124. doi: 10.1128/jvi.58.1.116-124.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gaines H., Albert J., von Sydow M., Sönnerborg A., Chiodi F., Ehrnst A., Strannegård O., Asjö B. HIV antigenaemia and virus isolation from plasma during primary HIV infection. Lancet. 1987 Jun 6;1(8545):1317–1318. doi: 10.1016/s0140-6736(87)90570-8. [DOI] [PubMed] [Google Scholar]
  15. Gajdusek D. C., Amyx H. L., Gibbs C. J., Jr, Asher D. M., Rodgers-Johnson P., Epstein L. G., Sarin P. S., Gallo R. C., Maluish A., Arthur L. O. Infection of chimpanzees by human T-lymphotropic retroviruses in brain and other tissues from AIDS patients. Lancet. 1985 Jan 5;1(8419):55–56. doi: 10.1016/s0140-6736(85)91011-6. [DOI] [PubMed] [Google Scholar]
  16. Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478–4482. doi: 10.1073/pnas.85.12.4478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Goudsmit J., Epstein L. G., Paul D. A., van der Helm H. J., Dawson G. J., Asher D. M., Yanagihara R., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C. Intra-blood-brain barrier synthesis of human immunodeficiency virus antigen and antibody in humans and chimpanzees. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3876–3880. doi: 10.1073/pnas.84.11.3876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Goudsmit J., Ljunggren K., Smit L., Jondal M., Fenyö E. M., Jonda M. Biological significance of the antibody response to HIV antigens expressed on the cell surface. Arch Virol. 1988;103(3-4):189–206. doi: 10.1007/BF01311092. [DOI] [PubMed] [Google Scholar]
  19. Goudsmit J., Smit L., Klaver B., Asher D. M., Wolff A., Gibbs C. J., Jr, Gajdusek D. C. Induction in chimpanzees of antibodies inhibiting receptor-mediated cell fusion by HIV glycoprotein. Viral Immunol. 1987;1(3):225–240. doi: 10.1089/vim.1987.1.225. [DOI] [PubMed] [Google Scholar]
  20. Goudsmit J., Smit L., Krone W. J., Bakker M., van der Noordaa J., Gibbs C. J., Epstein L. G., Gajdusek D. C. IgG response to human immunodeficiency virus in experimentally infected chimpanzees mimics the IgG response in humans. J Infect Dis. 1987 Feb;155(2):327–331. doi: 10.1093/infdis/155.2.327. [DOI] [PubMed] [Google Scholar]
  21. Goudsmit J., Thiriart C., Smit L., Bruck C., Gibbs C. J. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees. Vaccine. 1988 Jun;6(3):229–232. doi: 10.1016/0264-410x(88)90216-2. [DOI] [PubMed] [Google Scholar]
  22. Goudsmit J., de Wolf F., Paul D. A., Epstein L. G., Lange J. M., Krone W. J., Speelman H., Wolters E. C., Van der Noordaa J., Oleske J. M. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet. 1986 Jul 26;2(8500):177–180. doi: 10.1016/s0140-6736(86)92485-2. [DOI] [PubMed] [Google Scholar]
  23. Haase A. T. Pathogenesis of lentivirus infections. Nature. 1986 Jul 10;322(6075):130–136. doi: 10.1038/322130a0. [DOI] [PubMed] [Google Scholar]
  24. Hahn B. H., Shaw G. M., Taylor M. E., Redfield R. R., Markham P. D., Salahuddin S. Z., Wong-Staal F., Gallo R. C., Parks E. S., Parks W. P. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science. 1986 Jun 20;232(4757):1548–1553. doi: 10.1126/science.3012778. [DOI] [PubMed] [Google Scholar]
  25. Ho D. D., Kaplan J. C., Rackauskas I. E., Gurney M. E. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science. 1988 Feb 26;239(4843):1021–1023. doi: 10.1126/science.2830667. [DOI] [PubMed] [Google Scholar]
  26. Ho D. D., Sarngadharan M. G., Hirsch M. S., Schooley R. T., Rota T. R., Kennedy R. C., Chanh T. C., Sato V. L. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol. 1987 Jun;61(6):2024–2028. doi: 10.1128/jvi.61.6.2024-2028.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hu S. L., Fultz P. N., McClure H. M., Eichberg J. W., Thomas E. K., Zarling J., Singhal M. C., Kosowski S. G., Swenson R. B., Anderson D. C. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 1987 Aug 20;328(6132):721–723. doi: 10.1038/328721a0. [DOI] [PubMed] [Google Scholar]
  28. Kennedy-Stoskopf S., Narayan O. Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence. J Virol. 1986 Jul;59(1):37–44. doi: 10.1128/jvi.59.1.37-44.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Looney D. J., Fisher A. G., Putney S. D., Rusche J. R., Redfield R. R., Burke D. S., Gallo R. C., Wong-Staal F. Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science. 1988 Jul 15;241(4863):357–359. doi: 10.1126/science.3388046. [DOI] [PubMed] [Google Scholar]
  30. Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K., Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol. 1988 Jun;62(6):2107–2114. doi: 10.1128/jvi.62.6.2107-2114.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Matthews T. J., Langlois A. J., Robey W. G., Chang N. T., Gallo R. C., Fischinger P. J., Bolognesi D. P. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9709–9713. doi: 10.1073/pnas.83.24.9709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. McKeating J. A., Gow J., Goudsmit J., Pearl L. H., Mulder C., Weiss R. A. Characterization of HIV-1 neutralization escape mutants. AIDS. 1989 Dec;3(12):777–784. doi: 10.1097/00002030-198912000-00001. [DOI] [PubMed] [Google Scholar]
  33. Meloen R. H., Liskamp R. M., Goudsmit J. Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. J Gen Virol. 1989 Jun;70(Pt 6):1505–1512. doi: 10.1099/0022-1317-70-6-1505. [DOI] [PubMed] [Google Scholar]
  34. Nara P. L., Hatch W. C., Dunlop N. M., Robey W. G., Arthur L. O., Gonda M. A., Fischinger P. J. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses. 1987 Fall;3(3):283–302. doi: 10.1089/aid.1987.3.283. [DOI] [PubMed] [Google Scholar]
  35. Nara P. L., Robey W. G., Arthur L. O., Asher D. M., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C., Fischinger P. J. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. J Virol. 1987 Oct;61(10):3173–3180. doi: 10.1128/jvi.61.10.3173-3180.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Nara P. L., Robey W. G., Pyle S. W., Hatch W. C., Dunlop N. M., Bess J. W., Jr, Kelliher J. C., Arthur L. O., Fischinger P. J. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol. 1988 Aug;62(8):2622–2628. doi: 10.1128/jvi.62.8.2622-2628.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Nara P., Hatch W., Kessler J., Kelliher J., Carter S. The biology of human immunodeficiency virus-1 IIIB infection in the chimpanzee: in vivo and in vitro correlations. J Med Primatol. 1989;18(3-4):343–355. [PubMed] [Google Scholar]
  38. Narayan O., Clements J. E., Griffin D. E., Wolinsky J. S. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun. 1981 Jun;32(3):1045–1050. doi: 10.1128/iai.32.3.1045-1050.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nicolaisen-Strouss K., Kumar H. P., Fitting T., Grant C. K., Elder J. H. Natural feline leukemia virus variant escapes neutralization by a monoclonal antibody via an amino acid change outside the antibody-binding epitope. J Virol. 1987 Nov;61(11):3410–3415. doi: 10.1128/jvi.61.11.3410-3415.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Palker T. J., Clark M. E., Langlois A. J., Matthews T. J., Weinhold K. J., Randall R. R., Bolognesi D. P., Haynes B. F. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932–1936. doi: 10.1073/pnas.85.6.1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Putney S. D., Matthews T. J., Robey W. G., Lynn D. L., Robert-Guroff M., Mueller W. T., Langlois A. J., Ghrayeb J., Petteway S. R., Jr, Weinhold K. J. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science. 1986 Dec 12;234(4782):1392–1395. doi: 10.1126/science.2431482. [DOI] [PubMed] [Google Scholar]
  42. Robert-Guroff M., Reitz M. S., Jr, Robey W. G., Gallo R. C. In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol. 1986 Nov 15;137(10):3306–3309. [PubMed] [Google Scholar]
  43. Rusche J. R., Javaherian K., McDanal C., Petro J., Lynn D. L., Grimaila R., Langlois A., Gallo R. C., Arthur L. O., Fischinger P. J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A. 1988 May;85(9):3198–3202. doi: 10.1073/pnas.85.9.3198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rübsamen-Waigmann H., Becker W. B., Helm E. B., Brodt R., Fischer H., Henco K., Brede H. D. Isolation of variants of lymphocytopathic retroviruses from the peripheral blood and cerebrospinal fluid of patients with ARC or AIDS. J Med Virol. 1986 Aug;19(4):335–344. doi: 10.1002/jmv.1890190406. [DOI] [PubMed] [Google Scholar]
  45. Saag M. S., Hahn B. H., Gibbons J., Li Y., Parks E. S., Parks W. P., Shaw G. M. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature. 1988 Aug 4;334(6181):440–444. doi: 10.1038/334440a0. [DOI] [PubMed] [Google Scholar]
  46. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuchi R., Horn G. T., Mullis K. B., Erlich H. A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988 Jan 29;239(4839):487–491. doi: 10.1126/science.2448875. [DOI] [PubMed] [Google Scholar]
  47. Salinovich O., Payne S. L., Montelaro R. C., Hussain K. A., Issel C. J., Schnorr K. L. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection. J Virol. 1986 Jan;57(1):71–80. doi: 10.1128/jvi.57.1.71-80.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Tersmette M., Gruters R. A., de Wolf F., de Goede R. E., Lange J. M., Schellekens P. T., Goudsmit J., Huisman H. G., Miedema F. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol. 1989 May;63(5):2118–2125. doi: 10.1128/jvi.63.5.2118-2125.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Tersmette M., Lange J. M., de Goede R. E., de Wolf F., Eeftink-Schattenkerk J. K., Schellekens P. T., Coutinho R. A., Huisman J. G., Goudsmit J., Miedema F. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet. 1989 May 6;1(8645):983–985. doi: 10.1016/s0140-6736(89)92628-7. [DOI] [PubMed] [Google Scholar]
  51. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986 Dec 11;324(6097):572–575. doi: 10.1038/324572a0. [DOI] [PubMed] [Google Scholar]
  52. Willey R. L., Ross E. K., Buckler-White A. J., Theodore T. S., Martin M. A. Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol. 1989 Sep;63(9):3595–3600. doi: 10.1128/jvi.63.9.3595-3600.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. von Briesen H., Becker W. B., Henco K., Helm E. B., Gelderblom H. R., Brede H. D., Rübsamen-Waigmann H. Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning. J Med Virol. 1987 Sep;23(1):51–66. doi: 10.1002/jmv.1890230107. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES